Introduction
Oculocutaneous albinism (OCA, OMIM #203100) is the most common inherited disorder of skin pigmentation and affects 1 in every 18,000 people in the United States [1] . Oculocutaneous albinism type 2 (OCA2), the most common OCA type, is caused by mutations of the OCA2 gene. The human OCA2 gene (formerly called the P gene), located at chromosome 15q11.2-q12, is the homolog of the mouse pink-eyed dilution gene (p) [2, 3] . The OCA2 gene is comprised of 24 exons, the first representing a noncoding 5 0 UTR [4] . Although its function is not precisely characterized, the OCA2 gene product, the P-protein, contains 12 transmembrane spanning regions and is an integral component of the melanosomal membrane [3] [4] [5] . It appears to have multiple functions in the biosynthesis of melanin including a key role in the maturation and transport of tyrosinase into the melanosome [6, 7] . To date, 117 OCA2 mutations have been reported in the Human Gene Mutation Database (HGMDin part be explained by the high frequency OCA2 variants in individuals of African descent [9] . While the increased rates of MM among individuals with OCA2 may be entirely accounted for by the reduction of melanin, several published reports suggest that OCA2 variants, which in and of themselves do not cause albinism, may represent an inherited biomarker of MM susceptibility independent of its role in human pigmentation [10] [11] [12] . However, other similar genome wide association studies (GWAS) have failed to demonstrate this association [13, 14] . The identification of a new OCA2 variant within a melanoma-prone pedigree provides an opportunity to study the association between OCA2 variants and the risk of MM.
Here, we present the case of a 45-year-old Caucasian male with OCA2 and a positive family history of melanoma who was later determined to carry mutations in both OCA2 alleles: a previously reported conservative missense mutation (V443I) and a novel nonconservative missense mutation (L734R). In this study we examined the OCA2 status of those family members with and without a history of MM to investigate the effects of this polymorphism on MM susceptibility in this pedigree.
Materials and methods

Study subjects
The proband, a previously undiagnosed 45-year-old Caucasian male, presented to our Familial Melanoma Research Clinic (IRB# 7616) at the Huntsman Cancer Institute. He was a member of a non-consanguineous pedigree (Fig. 1 ) containing 4 melanoma patients and 11 unaffected individuals in 4 generations. We attempted to contact all living members of this family as well as obtain a next of kin consent for any deceased individuals. We were successful in enrolling eight individuals (Study Subjects 1-8), including four patients with a personal history of melanoma. Unfortunately, we were unable to obtain DNA for one of these deceased melanoma patients (Study Fig. 1 . Pedigree and group photo of family with oculocutaneous albinism 2 (OCA2) and malignant melanoma (MM). (Study Subjects, left to right: 8 holding a child, 5, 4, 7, and a daughter of 7.) Consent for this photo was obtained from all individuals shown. Subject 6) as there were no available archived tissue specimens from previous surgeries.
The proband had red-blonde hair, light blue eyes, and fair skin ( Fig. 2A-C) and a complete skin exam revealed numerous pink to light brown nevi randomly distributed on his body (Fig. 2D) as well as signs of photodamage. Physical examination also revealed nystagmus.
Proband microscopic analysis
A 5 mm punch biopsy of normal appearing skin was obtained from the proband's left buttock. Sections were then prepared for immunohistochemical analysis and light microscopy according to standard protocols. The Hematoxylin and Eosin (H&E) stained sections demonstrated normal epidermis with melanocytic cells regularly distributed along the dermoepidermal junction (Fig. 3A) . A Fontana-Masson stain for melanin, however, did not demonstrate terminal melanin synthesis (Fig. 3B) . A Melan-A immunostain was reactive with the scattered dermoepidermal junctional melanocytes (Fig. 3C ). This finding is indicative of at least premelanosome differentiation, a finding confirmed later by transmission electron microscopy (TEM). Sections of tissue were prepared for TEM by placing a new biopsy in EM fixative (2.5% glutaraldehyde and 1% paraformaldehyde in 0.1 M sodium cacodylate). The tissue was rinsed in 0.1 M sodium cacodylate then postfixed in 2% osmium tetroxide in 0.1 M sodium cacodylate for 45 min and rinsed in nanopure water. The tissue was then stained in saturated aqueous uranyl acetate for 45 min and dehydrated in a series of ethanols (50%, 75%, 95%, and 100% ethanol) to 100% propylene oxide. The tissue was then infiltrated with increasing concentrations of unpolymerized plastic and placed in Beem capsules (Ted Pella, Inc., Redding, CA) in Epon and heat polymerized under standard conditions, sectioned, and stained with uranyl acetate and lead citrate. TEM showed relatively spherical organelles within the basal layer of the epidermis with moderately abundant amorphous protein substance, possibly matrix proteins unable to align into filaments (Fig. 3D) . The shape and luminal content of these organelles is most compatible with a classification of aberrant stage II melanosomes, a finding common in patients with OCA2 gene mutations [15] . The clinical features of this patient, coupled with light and electron micrographic analyses of the skin biopsies, led us to make a clinical diagnosis of oculocutaneous albinism type 2 (OCA2).
Nucleic acid isolation and PCR amplification
DNA was extracted from whole blood samples collected in Acid Citrate Dextrose (ACD) Venous Blood Vacuum Collection Tubes and/or saliva samples collected using the Oragene 1 DNA Sample Collection Kit. DNA and RNA were isolated from peripheral blood leukocytes using the Qiagen Genomic DNA Isolation Kit and RNEasy Kit, respectively. DNA purity and concentration was determined using the NanoDrop 2000 Spectrophotometer (Thermo Scientific). Polymerase Chain Reaction (PCR) was used to amplify exons 2-24 of OCA2 in the proband using primers described by King et al. [16] . In all other study subjects, exons 13 and 21 of OCA2 (exons demonstrating the OCA2 mutations), exons 2-8 of TYRP1, and MC1R were amplified using primers listed in Table 1 . All PCR primers were designed and purchased from the University of Utah's DNA Sequencing and Genomics Core Facility.
For all PCR reactions, 1 mL of genomic DNA [50 ng/mL] was used as a PCR template in 20 mL total reaction volume containing 2 mL 10Â PCR Buffer (Denville Scientific, Inc.), 1.6 mL 2.5 mM dNTP Mix (Invitrogen), 1 mL of each forward and reverse primer [10 mM], 13.2 mL H 2 O, and 0.2 mL Hot-Start Taq (5 U/mL) (Denville Scientific, Inc.). The conditions for PCR amplification were 95 8C for 5 min followed by 35 cycles of 95 8C for 15 s, 60 8C for 20 s, and 72 8C for 20 s. Following amplification, 3 mL of product and 1 mL of 1 kb Plus DNA Ladder (Invitrogen) were loaded and run on 1% agarose gels at 100 V for 30 min and DNA bands were visualized on a UV transilluminator after ethidium bromide staining. All PCR products where then purified using the ExoSAP-IT PCR Cleanup Protocol (Affymetrix/USB).
cDNA cloning
cDNA was produced from RNA of the proband using oligo-dT primers. The OCA2 gene message was amplified using primers beginning at the ATG start site and ending at the TAA stop codon. The amplified fragments were cloned using the TOPO TA Cloning kit from Invitrogen. Individual cDNA clones were then submitted for sequencing.
Genetic analysis of study subjects
Approximately 30 ng of purified PCR product was sent to the University of Utah's DNA Sequencing and Genomics Core Facility for direct sequencing. OCA2 and melanocortin 1 receptor (MC1R) genotype analyses were performed on all enrolled study subjects. The proband was also tested for mutations in the TYRP1 (tyrosinase-related protein 1) gene to rule out the possibility of 
Table 1
Primers used to amplify OCA2, TYRP1, and MC1R coding sequences.
Gene
Exon Forward primer Reverse primer
oculocutaneous albinism type 3 (OCA3). TYR was not screened as the proband's history and phenotype was inconsistent with oculocutaneous albinism type 1 (OCA1). Additionally, DNA from two of the three cutaneous melanoma patients was sent for p16, p19/ARF, and CDK4 genotyping analyses (GeneDx, Gaithersburg, MD) to rule out other several known heritable causes of melanoma. DNA from the third cutaneous melanoma patient (Study Subject 6) was not sent for p16, p19/ARF, and CDK4 genotyping analyses as the patient is deceased and there were no available archived tissue specimens. Sequencher 4.10.1 software was used to align and analyze all sequencing results with reference sequences found in the UCSC Genome Browser. All mutations were confirmed by direct sequencing of both strands with both forward and reverse primers.
Segregation analysis
We assessed the relationship between the OCA2 variant(s) and melanoma using the pedigree likelihood-based method of Thompson et al. which uses all pedigree genotype and phenotype information in deriving the odds of pathogenecity vs. neutral with respect to disease risk [17] . In short, this model allows one to evaluate the evidence for causality associated with a particular DNA variant (e.g. OCA2) with reference to the disease of interest (e.g. MM) in a single affected pedigree. This method has been extensively used for the assessment of variants of unknown significance in families undergoing testing for BRCA1 and BRCA2 gene mutations [18] [19] [20] .
Results
MC1R sequencing of the proband revealed no gene mutations. Likewise, TYRP1 sequence analysis revealed only single nucleotide polymorphisms (SNPs) in intron sequences. However, OCA2 gene sequence analysis of the proband (Table 2) showed two missense mutations, one in exon 13 (V443I) and a second in exon 21 (L734R). Two separate clones, each containing only one of the mutations, were isolated in cDNA cloning experiments, thereby demonstrating that the V443I and L734R mutations were located on separate alleles. Additionally, we identified three SNPs in exons 10, 15, and 22 as well as four intronic region polymorphisms.
Available protein structural information allowed us to localize the V443I and L734R amino acid changes to 5th and 10th transmembrane domains, respectively. The V443I mutation in exon 13 has been described by Oetting et al. [21] and is associated with oculocutaneous albinism in humans. L734R occurs in the midsection of helix number 10. The change in the amino acid side chain from a hydrophobic leucine residue to a positively charged arginine likely results in the disruption of this transmembrane domain. The coincidence of the L734R with a known diseaseassociated allele and the oculocutaneous phenotype described above, strongly suggest that the L734R mutation results in loss of or significant compromise of function in the P-protein.
The V443I variant appears to be quite uncommon in the general population as it was identified in only 54/8546 European and 10/ 4396 African American exomes listed on the exome variant server (minor allele frequency 0.0063). Thus, this variant is found in approximately 1.2% of individuals in the general population. In contrast, the L734A variant was not observed in the 12,000 sequenced exomes listed on exome variant server, nor was it identified in 4000 African American chromosomes. While these observations do not represent true population controls, they do provide some idea of the frequencies of these variants in the general population.
The genotyping analyses of Study Subjects 1-8 are summarized in Table 3 . OCA2 sequencing of exons 13 and 21 revealed a single V443I mutation in Study Subject 5 and both of the V443I and L734R mutations in Study Subject 2, who is described by the family as 
Gene
Mutation Location Nomenclature Sequence Amino acid substitution sharing the same phenotype as the proband. Interestingly, both of these study subjects also have a personal history of cutaneous melanoma. OCA2 sequencing of the remaining study subjects revealed normal sequence. MC1R sequencing revealed a single D294H mutation in Study Subjects 1, 3 and 5. Study Subjects 7 and 8 had both the V92M and T314T MC1R mutations, while Study Subjects 2 and 4 had wild-type sequence. p16, p19/ARF, and CDK4 genotyping analyses in Study Subject 5 and 7 were negative. The pigmentary characteristics and nevus phenotype of the study subjects can also be found in Table 3 . Other than cervical cancer diagnosed at the age of 28 in Study Subject 4, there were no other reported non-skin cancers in this pedigree arguing against an underlying familial cancer syndrome. Using a full pedigree likelihood-based method to evaluate the causality of the OCA2 variant(s) on MM risk, we assumed (1) a model of a rare dominant susceptibility locus conferring a risk of 0.4 for carriers and 0.02 for non-carriers and (2) that both of the OCA2 alleles observed in the index case conferred this risk, with no added risk of CMM in carriers of both variants. Based on cosegregation analysis, the odds of the V443I OCA2 variant being a high penetrance locus for melanoma is: 1.3-to-1 if we include the iris melanoma as affected and 6.6-to-1 if we only consider cutaneous melanoma as affected. When both OCA2 variants (i.e. V443I and L734A) are incorporated into the pedigree co-segregation analysis simultaneously, the results are 1.33-to-1 if we include the iris melanoma as affected and 6.55-to-1 if we only consider cutaneous melanoma as affected.
Discussion
Pigmentation is one of the most visible human phenotypic traits. Albinism (Latin, albus, meaning ''white'') represents a heterogeneous disease characterized by defective melanin synthesis despite adequate numbers of structurally normal melanocytes in the skin and eye [22] . The current classification of albinism is determined by the affected gene and allows differentiation between ocular, oculocutaneous, and other types of albinism including those associated with systemic disease. Oculocutaneous albinism (OCA), an autosomal-recessive pleiotropic disease, results in reduced melanin synthesis in the melanocyte and consequent generalized hypopigmentation of the skin, hair, and eyes. It is also associated with ocular abnormalities including nystagmus, foveal hypoplasia, deficient retinal pigment, transillumination of the iris, reduced visual acuity, photophobia, and misrouting of the optic tract resulting in alternating strabismus [22, 23] .
A clinical diagnosis of OCA requires the presence of hypopigmentation characteristics as well as clinical or electrophysiological (i.e. asymmetric visual-evoked potentials) evidence of the associated ocular abnormalities mentioned above [22, 24] . Presently, there are four major types (types 1-4) of non-syndromic OCA (Table 4 ). However, due to the broad phenotypic variation and considerable overlap between these different types, OCA is now considered a genetic diagnosis.
Oculocutaneous albinism type 1 (OCA1), the most severe form of OCA, is associated with mutations in the tyrosinase (TYR) gene which encodes tyrosinase, the rate-limiting enzyme in the melanin biosynthetic pathway [25] . Located at 11q14-q21, this copperdependant enzyme catalyzes the hydroxylation of tyrosine to DOPAquinone, from which both types of melanin known as eumelanin and pheomelanin are derived [26] [27] [28] . Oculocutaneous albinism type 2 (OCA2) is caused by mutations in the human OCA2 gene resulting in alterations in the P-protein, thereby disrupting its role in melanin biosynthesis [7] . Oculocutaneous albinism type 3 (OCA3), formerly known as Rufous OCA, is a mild form of albinism seen predominantly in South African blacks and is the result of mutations in the tyrosinase-related protein 1 (TYRP1) gene located at 9p23 [29] [30] [31] . The TYRP1 gene codes for the TYRP1 protein, an enzyme which may act downstream of tyrosinase in the eumelanin pathway [32, 33] . Oculocutaneous albinism type 4 (OCA4), one of the major types of OCA in Japanese populations, is due to mutations in the SLC45A2 (solute carrier family 45 member 2) gene [34] . Located at 5p13.3, the SLC45A2 gene encodes for the membrane associated transporter (MATP) protein, a transporter thought to be involved in the sorting of melanosomal enzymes during melanogenesis [35, 36] .
OCA2 accounts for approximately 50% of OCA cases worldwide and is estimated to affect nearly 1 in 36,000 people in the United States [9, 37, 38] . Located at chromosome 15q11.2-q12, the OCA2 gene spans 345 kbp of DNA and is composed of 25 exons, 24 coding exons and one containing a noncoding 5 0 UTR [4] . The OCA2 gene product, the P-protein, is an 838-amino acid polypeptide containing 12 transmembrane spanning regions in an arrangement resembling that of other small molecule transporters [3] [4] [5] . Expressed almost exclusively in melanocytes, the specific function of the P-protein is not entirely clear. However, numerous studies suggest that its function as an integral component of the melanosome membrane and may involve the processing and trafficking of proteins to the melanosome [12, 15, [39] [40] [41] , stabilization of the melanosomal protein complex [41, 42] , regulation of melanosomal pH [43] , arsenic sensitivity [44] , and intracellular glutathione metabolism [44] . Regardless of its specific function, OCA2 gene mutations result in a significant reduction in melanogenesis thus demonstrating the continued need for mutational analyses in patients with phenotypic characteristics of albinism. Such studies are not only informative regarding the etiology of OCA but necessary to accurately diagnose individuals affected by this disease.
Numerous publications and recent genome-wide association studies (GWAS) support the genomic association of this locus with regulation of pigmentation traits including eye, hair, and skin color, the association with eye color being the strongest [14, 45, 46] . This association is further supported by the observation that deletion of this same chromosomal region in PraderWilli and Angelman syndromes results in hypopigmentation characteristics. Additionally, studies have shown that the classic phenotype and constitutive mRNA expression of the OCA2 gene is modified by other genomic regions linked to pigmentation characteristics, including the MC1R gene [16] . Lastly, several publications have also reported an association between specific OCA2 gene polymorphisms and cutaneous malignant melanoma (CMM) risk even after stratification for MC1R variants and/or pigmentation characteristics (such as eye, hair and skin colors, nevi count, and skin type) [10] [11] [12] .
Interestingly, the reported association between specific OCA variants and increased MM risk does not appear evenly distributed among the different OCA types despite the fact that all forms of this disease are characterized by defective melanin synthesis. While this observation may be due to genetic and/or environmental differences between the populations carrying these polymorphisms, it may offer some insight into the underlying mechanism by which specific OCA variants confer an increased MM risk independent of their role in pigmentation. Specifically, paying particular attention to the many reported P-protein functions (e.g. intracellular glutathione metabolism) when investigating the association between OCA2 variants and MM risk may shed light on the biological mechanism in which these variants confer an increased MM risk and, ultimately, enhance our understanding of MM pathogenesis.
Limitations of this study include the small sample size and a limited number of MM cases in this single family. However, it is possible that individuals carrying OCA2 variants despite no personal history of melanoma, such as the proband, may yet develop MM at a later date. We also acknowledge that one of the MM cases in this pedigree is a non-cutaneous (iris) melanoma and may therefore represent a sporadic case that is unrelated to the increased MM susceptibility in this pedigree. It was for this reason that we used two different models to evaluate the causality of the OCA2 variant(s) on MM risk: one including and the other excluding the ocular melanoma as affected. This study is also not a complete survey of all of the genes involved in pigmentation which are thought to confer some increased MM susceptibility and the full pedigree likelihood-based analysis model does not attempt to decipher the complex interaction between these known genetic variants (such as MC1R) and MM susceptibility. This type of gene-gene interaction may be relevant to this pedigree because subject 5 was shown to have variants in both the MC1R and OCA2 genes and was also one of the subjects with severe photodamage and a history of multiple non-melanoma skin cancers in addition to melanoma. Therefore, it is necessary that further studies be done and our hypothesis considered in a larger sample size before any final conclusion can be drawn. Despite these limitations, this very unusual and interesting melanoma pedigree represents an ''experiment of nature'' worth exploring at the genetic level. To our knowledge, this is the first report of a study looking at the association of specific OCA2 variants and MM in a familial melanoma pedigree.
In summary, we report a novel OCA2 gene mutation found in a previously undiagnosed 45-year-old Caucasian male with a typical OCA2 phenotype and nystagmus as well as the results of our investigation of this polymorphism on MM susceptibility in a pedigree with familial melanoma. The proband was determined to be an OCA2 gene compound heterozygous mutation carrier with a previously reported conservative missense mutation of one OCA2 gene allele (GTC-ATC, Val443Ile) and a novel non-conservative missense mutation of the other OCA2 gene allele (CTG-CGG, Leu734Arg). This adds to the body of evidence on the detrimental effects of OCA2 gene mutations on pigmentation. Further research and analysis is required to determine the specific biological role of this novel mutation and its impact on the P-protein structure. Such information will enhance our understanding of human pigmentation pathways and may ultimately result in information leading to the future development and use of targeted molecular therapies in the treatment of OCA and MM.
